ASH 2017: ECHELON-1: Brentuximab vedotin plus AVD in HL produces PFS improvement
Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.